​

Vera Therapeutics (VERA) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

VERA Stock Forecast

Vera Therapeutics (VERA) stock forecast, based on 9 Wall Street analysts, predicts a 12-month average price target of $65.00, with a high of $65.00 and a low of $65.00. This represents a 188.63% increase from the last price of $22.52.

$15 $25 $35 $45 $55 $65 High: $65 Avg: $65 Low: $65 Last Closed Price: $22.52

VERA Stock Rating

Vera Therapeutics stock's rating consensus is Buy, based on 9 Wall Street analysts. The breakdown includes 1 Strong Buy (11.11%), 7 Buy (77.78%), 1 Hold (11.11%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 9 0 1 7 1 Strong Sell Sell Hold Buy Strong Buy

VERA Price Target Upside V Benchmarks

TypeNameUpside
StockVera Therapeutics188.63%
SectorHealthcare Stocks 24.81%
IndustryBiotech Stocks 65.78%

Price Target Trends

1M3M12M
# Anlaysts111
Avg Price Target$65.00$65.00$65.00
Last Closing Price$22.52$22.52$22.52
Upside/Downside188.63%188.63%188.63%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 25491--14
May, 25391--13
Apr, 25391--13
Mar, 25391--13
Feb, 25481--13
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jun 03, 2025Greg HarrisonScotiabank$65.00$30.91110.29%188.63%
Mar 21, 2024Laura ChicoWedbush$34.00$42.87-20.69%50.98%
Jan 26, 2024Ryan DeschnerRaymond James$37.00$30.1822.60%64.30%
Dec 18, 2023Ryan DeschnerRaymond James$29.00$15.8483.08%28.77%
Jan 04, 2023Jefferies$6.00$6.37-5.81%-73.36%
Jan 04, 2023H.C. Wainwright$15.00$18.30-18.03%-33.39%
Nov 18, 2022J.P. Morgan$38.00$17.62115.66%68.74%
May 02, 2022H.C. Wainwright$35.00$20.0075.00%55.42%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jun 03, 2025ScotiabankOutperformOutperformhold
Jun 03, 2025GuggenheimBuyBuyhold
Jun 02, 2025H.C. WainwrightBuyBuyhold
Feb 04, 2025Wolfe ResearchOutperforminitialise
Oct 28, 2024GuggenheimBuyBuyhold
May 10, 2024Raymond JamesStrong BuyStrong Buyhold
Jan 26, 2024OppenheimerOutperforminitialise
Jan 26, 2024Raymond JamesStrong Buyupgrade
Nov 10, 2023JefferiesBuyupgrade
Jan 04, 2023GuggenheimBuyinitialise

Financial Forecast

EPS Forecast

$-5 $-4 $-3 $-2 $-1 $0 $1 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.25$-2.75----
Avg Forecast$-2.18$-2.83$-3.15$-3.04$-2.07$0.86
High Forecast$-2.11$-2.65$-2.23$-2.06$-0.09$0.86
Low Forecast$-2.26$-2.99$-4.73$-4.16$-3.80$0.86
Surprise %3.21%-2.83%----

Revenue Forecast

$0 $110M $220M $330M $440M $550M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$1.86M-----
Avg Forecast$1.86M$1.86M$1.86M$42.58M$210.59M$516.01M
High Forecast$1.86M$1.86M$1.86M$42.58M$210.59M$516.01M
Low Forecast$1.86M$1.86M$1.86M$42.58M$210.59M$516.01M
Surprise %------

Net Income Forecast

$-250M $-190M $-130M $-70M $-10M $50M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-95.99M$-152.15M----
Avg Forecast$-95.99M$-120.50M$-148.70M$-133.00M$-154.25M$36.57M
High Forecast$-90.22M$-113.19M$-95.27M$-88.17M$-4.04M$36.57M
Low Forecast$-96.57M$-127.81M$-202.13M$-177.82M$-162.30M$36.57M
Surprise %-26.26%----

VERA Forecast FAQ

Is Vera Therapeutics stock a buy?

Vera Therapeutics stock has a consensus rating of Buy, based on 9 Wall Street analysts. The rating breakdown includes 1 Strong Buy, 7 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Vera Therapeutics is a favorable investment for most analysts.

What is Vera Therapeutics's price target?

Vera Therapeutics's price target, set by 9 Wall Street analysts, averages $65 over the next 12 months. The price target range spans from $65 at the low end to $65 at the high end, suggesting a potential 188.63% change from the previous closing price of $22.52.

How does Vera Therapeutics stock forecast compare to its benchmarks?

Vera Therapeutics's stock forecast shows a 188.63% upside, outperforming the average forecast for the healthcare stocks sector (24.81%) and outperforming the biotech stocks industry (65.78%).

What is the breakdown of analyst ratings for Vera Therapeutics over the past three months?

  • June 2025: 28.57% Strong Buy, 64.29% Buy, 7.14% Hold, 0% Sell, 0% Strong Sell.
  • May 2025: 23.08% Strong Buy, 69.23% Buy, 7.69% Hold, 0% Sell, 0% Strong Sell.
  • April 2025: 23.08% Strong Buy, 69.23% Buy, 7.69% Hold, 0% Sell, 0% Strong Sell.

What is Vera Therapeutics’s EPS forecast?

Vera Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-3.15, marking a 14.55% increase from the reported $-2.75 in 2024. Estimates for the following years are $-3.04 in 2026, $-2.07 in 2027, and $0.86 in 2028.

What is Vera Therapeutics’s revenue forecast?

Vera Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $1.86M, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $42.58M, followed by $210.59M for 2027, and $516.01M for 2028.

What is Vera Therapeutics’s net income forecast?

Vera Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-149M, representing a -2.26% decrease from the reported $-152M in 2024. Projections indicate $-133M in 2026, $-154M in 2027, and $36.57M in 2028.